psilocybin high dose (WP002)
/ Woke Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 27, 2024
Swinburne Three-dose Psilocybin Assisted Psychotherapy (3PAP): a clinical trial of 2 vs 3 doses of psilocybin-assisted psychotherapy vs psychotherapy with placebo for Treatment-Resistant Depression
(ANZCTR)
- P2 | N=160 | Suspended | Sponsor: Swinburne University of Technology, Hawthorn | Recruiting ➔ Suspended
Trial suspension • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
October 06, 2023
Swinburne Three-dose Psilocybin Assisted Psychotherapy (3PAP): a clinical trial of 2 vs 3 doses of psilocybin-assisted psychotherapy vs psychotherapy with placebo for Treatment-Resistant Depression
(ANZCTR)
- P2 | N=160 | Recruiting | Sponsor: Swinburne University of Technology, Hawthorn | Not yet recruiting ➔ Recruiting
Enrollment open • Trial initiation date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
1 to 2
Of
2
Go to page
1